detorubicin

Also Known As:

14-diethoxyacetoxydaunorubicin; 33921 RP; R.P. 33 921; detrorubicin; Acetic acid, diethoxy-, 2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester, (2S-cis)-

Networked: 14 relevant articles (2 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasms (Cancer) 12/16/1982 - "Detorubicin is a new anthracyclin drug which has shown promise in the treatment of these tumors in a previous trial. " 01/01/1980 - "A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. " 01/01/1980 - "A phase II trial of detorubicin (DTR) has been conducted on 164 patinets with solid tumors. " 01/01/1980 - "Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin." 05/01/1979 - "Detorubicin showed a high activity in mycosis fungoides (five regressions among six patients) and some activity in soft tissue sarcomas, osteosarcomas, and various solid tumors."
2.	Leukemia L1210 05/01/1979 - "The therapeutic effect of detorubicin on the sc implanted L1210 leukemia is superior to that of daunorubicin and at least equal to that of Adriamycin. " 05/01/1979 - "Golden hamsters received Adriamycin (ADR), detorubicin (DTR), AD-32, or aclacinomycin (ACM) three times weekly at doses extrapolated from optimal doses in L1210 leukemia. " 01/01/1979 - "administration during 4 weeks of 8 anthracyclines, adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (eADM), adriamycin hydrochloride (ADMh), rubidazon (RBZ), aclacinomycin (ACM) and AD32, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. " 01/01/1980 - "Golden hamsters were administered seven anthracyclines: adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (eADM), rubidazone (RBZ), aclacinomycin (ACM), and N-trifluoroacetyladriamycin-14-valerate (AD-32), three times a week during 4 weeks, at doses equivalent to 3/4 of those which are optimally oncostatic on murine L1210 leukemia. " 01/01/1984 - "administration of an antracenedione, mitoxantrone (MTX), and 12 different anthracyclines, adriamycin (ADM), detorubicin (DTR), daunorubicin (DNR), 4'-epi-adriamycin (e-ADM), rubidazone (RBZ), aclacinomycin (ACM), N-trifluoroacetyladriamycin-14-valerate (AD-32), tetrahydropyranyl-adriamycin (THP-ADM), N-L-leucyl-daunorubicin (l-DNR), carminomycin (CAM), rubicyclamin (RBC) and N-trifluoroacetyl-adriamycin-14-9-hemiadipate (AD-143), at doses equivalent to 3/4 those which are optimally oncostatic on murine L1210 leukemia. "
3.	Melanoma (Melanoma, Malignant) 11/01/1985 - "In contrast to Adriamycin, detorubicin has shown activity in previously untreated patients with metastatic melanoma." 11/01/1985 - "Detorubicin--an active anthracycline in untreated metastatic melanoma." 11/01/1985 - "A phase II study of detorubicin, the semisynthetic 14-diethoxyacetoxy ester of daunorubicin, was conducted in 42 patients with metastatic melanoma. "
4.	Head and Neck Neoplasms (Head and Neck Cancer) 01/01/1981 - "[Randomized trial of vincristin-methotrexate-bleomycin and cis-platin or detorubicin for advanced head and neck cancer (author's transl)]."
5.	Alopecia (Baldness) 01/01/1978 - "This very low incidence of myocardial lesions and the absence of hair loss had been predicted, respectively, by our electron microscope study of the myocardium and the light electron microscope study of the skin of golden hamsters [7], a test that detects frequent severe myocardium and skin toxicities for adriamycin and some anthracyclin analogues such as detorubicin, which was found to be toxic in a high percentage of patients in a clinical trial conducted by the E.O.R.T.C. "

Related Drugs and Biologics

1.	Daunorubicin (Cerubidine)
2.	Doxorubicin (Adriamycin)
3.	Therapeutic Uses
4.	Methotrexate (Mexate)
5.	Esters
6.	Bleomycin (Blenoxane)
7.	Anthracyclines
8.	aclacinomycins
9.	Epirubicin (Ellence)
10.	zorubicin